Gilead Sciences, Inc. $GILD Shares Bought by Focus Partners Wealth

Key Points

• Focus Partners Wealth increased its stake in Gilead Sciences by 21.2% in Q1, owning 142,666 shares valued at approximately $15.99 million.
• Institutional ownership of Gilead Sciences stands at 83.67%, with various hedge funds making significant investments during the same period.
• Gilead reported earnings of $2.01 per share, beating estimates, and announced a $0.79 quarterly dividend with a yield of 2.8%.

Focus Partners Wealth boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 142,666 shares of the biopharmaceutical company's stock after buying an additional 24,930 shares during the period. Focus Partners Wealth's holdings in Gilead Sciences were worth $15,986,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences during the first quarter worth $25,000. Activest Wealth Management boosted its stake in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences in the 1st quarter valued at $29,000. Colonial Trust Advisors lifted its stake in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its stake in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the sale, the chief financial officer owned 160,110 shares in the company, valued at $18,977,838.30. This represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at approximately $978,880.80. The trade was a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,371,330 in the last quarter. Company insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent analyst reports. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. UBS Group upped their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Finally, Royal Bank Of Canada upped their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $114.55 on Friday. The stock's 50-day moving average is $114.04 and its two-hundred day moving average is $110.09. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1-year low of $81.57 and a 1-year high of $121.83. The company has a market cap of $142.13 billion, a price-to-earnings ratio of 22.82, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the prior year, the business earned $2.01 EPS. Gilead Sciences's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's dividend payout ratio is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.